Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Travere Therapeutics, Inc (TVTX)  
$5.26 0.13 (2.41%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 87,619,000
Market Cap: 460.88(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $5.39 - $22.61
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  993
Guru Rank Value     : 0
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Travere Therapeutics is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with kidney, liver, and metabolic diseases. Co.'s approved products include: Thiola and Thiola EC (tiopronin), which are approved for the treatment of cystinuria, a genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones; and Cholbam (cholic acid capsules), which is approved for the treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisome biogenesis disorder-Zellweger spectrum disorder.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 41,711 59,539 73,835 119,281
Total Sell Value $360,756 $522,023 $717,303 $1,724,035
Total People Sold 7 7 7 9
Total Sell Transactions 8 16 26 51
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 506
  Page 1 of 21  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Cline Christopher R. CHIEF FINANCIAL OFFICER   •       –      –    2024-04-11 4 S $6.74 $364 D/D (54) 70,849 19%     
   Reed Elizabeth E SVP, GC & CORPORATE SECRETARY   •       –      –    2024-02-01 4 AS $8.53 $41,495 D/D (4,764) 76,270 -39%     
   Rote William E. SENIOR VICE PRESIDENT, R&D   •       –      –    2024-02-01 4 AS $8.53 $41,495 D/D (4,764) 80,720 -39%     
   Cline Christopher R. CHIEF FINANCIAL OFFICER   •       –      –    2024-02-01 4 S $8.53 $32,573 D/D (3,818) 70,903 37%     
   Dube Eric M CHIEF EXECUTIVE OFFICER   •       •      –    2024-02-01 4 AS $8.53 $166,435 D/D (19,122) 350,600 -39%     
   Inrig Jula CHIEF MEDICAL OFFICER   •       –      –    2024-02-01 4 S $8.53 $18,547 D/D (2,174) 58,074 37%     
   Heerma Peter CHIEF COMMERCIAL OFFICER   •       –      –    2024-02-01 4 S $8.53 $35,789 D/D (4,195) 99,503 37%     
   Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER   •       –      –    2024-02-01 4 S $8.53 $24,058 D/D (2,820) 52,017 37%     
   Reed Elizabeth E SVP, GC & CORPORATE SECRETARY   •       –      –    2024-01-31 4 A $0.00 $0 D/D 25,000 81,034     -
   Rote William E. SENIOR VICE PRESIDENT, R&D   •       –      –    2024-01-31 4 A $0.00 $0 D/D 25,000 85,484     -
   Cline Christopher R. CHIEF FINANCIAL OFFICER   •       –      –    2024-01-31 4 A $0.00 $0 D/D 25,000 74,721     -
   Dube Eric M CHIEF EXECUTIVE OFFICER   •       •      –    2024-01-31 4 A $0.00 $0 D/D 135,000 369,722     -
   Inrig Jula CHIEF MEDICAL OFFICER   •       –      –    2024-01-31 4 A $0.00 $0 D/D 25,000 60,248     -
   Heerma Peter CHIEF COMMERCIAL OFFICER   •       –      –    2024-01-31 4 A $0.00 $0 D/D 25,000 103,698     -
   Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER   •       –      –    2024-01-31 4 A $0.00 $0 D/D 13,500 54,837     -
   Reed Elizabeth E SVP, GC & CORPORATE SECRETARY   •       –      –    2024-01-23 4 AS $8.96 $18,476 D/D (2,062) 56,034 -43%     
   Dube Eric M CHIEF EXECUTIVE OFFICER   •       •      –    2024-01-23 4 AS $8.96 $70,542 D/D (7,873) 234,722 -43%     
   Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER   •       –      –    2024-01-23 4 S $9.07 $8,252 D/D (910) 41,337 42%     
   Rote William E. SENIOR VICE PRESIDENT, R&D   •       –      –    2024-01-23 4 AS $8.96 $18,476 D/D (2,062) 60,484 -43%     
   Cline Christopher R. CHIEF FINANCIAL OFFICER   •       –      –    2024-01-23 4 S $9.07 $7,735 D/D (853) 49,721 42%     
   Heerma Peter CHIEF COMMERCIAL OFFICER   •       –      –    2024-01-23 4 S $9.07 $14,138 D/D (1,559) 78,698 42%     
   Inrig Jula Chief Medical Officer   •       –      –    2024-01-04 4 AS $9.17 $4,035 D/D (440) 35,248 -42%     
   Inrig Jula Chief Medical Officer   •       –      –    2024-01-03 4 AS $9.48 $19,613 D/D (2,069) 35,688 -42%     
   Heerma Peter Chief Commercial Officer   •       –      –    2023-10-03 4 S $8.25 $25,504 D/D (3,091) 80,257 -4%     
   Cline Christopher R. Chief Financial Officer   •       –      –    2023-09-05 4 S $14.71 $6,723 D/D (457) 50,574 33%     
  506 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 21
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us